Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
99.6M
-
Number of holders
-
588
-
Total 13F shares, excl. options
-
93.7M
-
Shares change
-
+811K
-
Total reported value, excl. options
-
$12.9B
-
Value change
-
+$111M
-
Put/Call ratio
-
0.34
-
Number of buys
-
320
-
Number of sells
-
-250
-
Price
-
$137.67
Significant Holders of NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) as of Q2 2024
681 filings reported holding NBIX - NEUROCRINE BIOSCIENCES INC - Common Stock as of Q2 2024.
NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) has 588 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 93.7M shares
of 99.6M outstanding shares and own 94.09% of the company stock.
Largest 10 shareholders include BlackRock Inc. (14.2M shares), VANGUARD GROUP INC (10.1M shares), STATE STREET CORP (4.61M shares), RENAISSANCE TECHNOLOGIES LLC (2.47M shares), JPMORGAN CHASE & CO (2.36M shares), Bellevue Group AG (1.9M shares), GEODE CAPITAL MANAGEMENT, LLC (1.82M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.8M shares), MORGAN STANLEY (1.54M shares), and Dodge & Cox (1.28M shares).
This table shows the top 588 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.